Sanarus raises $23m for breast cryoablation:
This article was originally published in Clinica
Pleasanton, California cryoablation specialist Sanarus Medical has closed a $23m financing round that will help it commercialise its products. The company's Visica ultrasound-guided system to treat breast fibroadenomas - or benign tumours - minimally invasively received FDA marketing clearance in 2001; it employs cryosurgical technology developed by Endocare, of Irvine, California. Sanarus also markets a breast biopsy device called Cassi. The financing was led by Pequot Ventures and current investors including Alta Partners, Technology Funding and US Venture Partners participated.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.